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Background: Previous pathological and in-vivo intravascular ultrasound (IVUS) studies has suggested that positive coronary arterial remodeling 
after first-generation drug-eluting stents was associated with late lumen catch-up and very late stent thrombosis. We evaluated vessel remodeling 
and peristent plaque change after zotarolimus-eluting stents (ZES) implantation in comparison with paclitaxel-eluting stents (PES) implantation, 
using gray-scale IVUS and integrated backscatter IVUS (IB-IVUS).
Methods: We randomly assigned 50 consecutive patients with de-novo lesions to treat with ZES (n=25) and PES (n=25). Serial volumetric IVUS 
analysis was performed after stenting and at 8 months follow-up. Peristent plaque (plaque outside stent struts) components were analyzed in 
the whole stent segment with the largest vessel site at baseline using IB-IVUS. We compared serial change of peristent plaque components, and 
evaluated the relationship between systemic inflammation scores (white blood cell fraction and high-sensitive C-reactive protein) and peristent 
plaque change in both groups.
Results: In PES, vessel volume in the whole stent segment significantly increased (365 to 389mm3, p<0.0001), whereas it did not change in 
ZES (315 to 314mm3, p=0.81). According to serial IB-IVUS analysis at the largest vessel site, fibrous plaque tended to increase (3.1 to 3.6mm2, 
p=0.051), whereas lipid plaque significantly increased (4.3 to 5.1mm2, p=0.02) in PES. In ZES, fibrous plaque significantly increased (2.9 to 
4.0mm2, p<0.0001), whereas lipid plaque significantly decreased (5.1 to 3.6mm2, p<0.0001). Lipid plaque change was not related to any systemic 
inflammation scores in ZES. However, lipid plaque change at the largest vessel site was significantly related to eosinophil change in PES (r=0.49, 
p=0.01). Late and very late stent thrombosis did not occur in either group up to 24 months follow-up.
Conclusions: Positive coronary arterial remodeling and chronic peristent lipid plaque gain occurred after PES implantation. As compared to PES, 
ZES could be potentially safe without positive vessel remodeling and inflammatory peristent plaque change.
